Melatonin: Clinical Perspectives in Neurodegeneration
Open accessThe DOI matches its Crossref record; 19 of the 19 references it cites were found in a registry or an index.
Abstract
Neurodegenerative diseases such as Alzheimer's disease (AD) and Parkinson's disease (PD) are important health problems and there is a growing recognition that both governmental and non-governmental organizations must make efforts to prevent, in addition to treat, them. In this context, the pineal product melatonin has a promising significance. Melatonin, an unusual phylogenetically conserved molecule present in all known aerobic organisms, is effective both as a chronobiotic and as a cytoprotective. As a chronobiotic, the afternoon increase in melatonin "opens the doors of sleep" every night and the therapeutic use of melatonin has been demonstrated to preserve slow wave sleep effectively. As a cytoprotective molecule, melatonin reverses the low degree inflammatory damage seen in neurodegenerative disorders and ageing. One of the characteristics of advancing age is the gradual decrease in the circulating levels of melatonin. Both in vitro and in vivo, melatonin prevented the neurodegeneration observed in experimental models of AD and PD. Melatonin also increased removal of toxic proteins by the brain glymphatic system. A limited number of clinical trials have indicated that melatonin has a potential therapeutic value as a neuroprotective drug in the treatment of AD, particularly at an early stage of cognitive impairment, and of PD. From animal studies the cytoprotective effects of melatonin need high doses to become apparent (i.e. in the 40-100 mg/day range). The off-label use of melatonin is discussed.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Dose translation from animal to human studies revisited.
Reagan‐Shaw, S., Nihal, M., & Ahmad, N. (2008) · The FASEB Journal · doi:10.1096/fj.07-9574lsf · Cited by 6,524 · cited 2×
“The human equivalent dose of melatonin for a 75 kg adult is calculated by normalization of body surface area (54).”
MethodIliff, J. J., Wang, M., Liao, Y., Plogg, B. A., Peng, W., Gundersen, G. A., Benveniste, H., Vates, G. E., Deane, R., Goldman, S. A., et al. (2012) · Science Translational Medicine · doi:10.1126/scitranslmed.3003748 · Cited by 5,824
The glymphatic system: a beginner's guide
Jessen, N. A., Munk, A. S. F., Lundgaard, I., & Nedergaard, M. (2015) · Neurochemical Research · doi:10.1007/s11064-015-1581-6 · Cited by 2,075 · cited 1×
“The term “glymphatic” describes active, lymphatic-like, water exchange movements in the brain extracellular space (ECS) driven by perivascular astrocytes, which contain aquaporin-4 (AQP4) located in their end feet (96).”
BackgroundImpairment of Glymphatic Pathway Function Promotes Tau Pathology after Traumatic Brain Injury
Iliff, J. J., Chen, M. J., Plog, B. A., Zeppenfeld, D. M., Soltero, M., Yang, L., Singh, I., Deane, R., & Nedergaard, M. (2014) · The Journal of Neuroscience · doi:10.1523/jneurosci.3020-14.2014 · Cited by 1,159
Melatonin—A pleiotropic, orchestrating regulator molecule
Hardeland, R., Cardinali, D. P., Srinivasan, V., Spence, D. W., Brown, G. M., & Pandi-Perumal, S. R. (2011) · Progress in Neurobiology · doi:10.1016/j.pneurobio.2010.12.004 · Cited by 843
Self-citationRiemersma-van der Lek, R. F. (2008) · JAMA · doi:10.1001/jama.299.22.2642 · Cited by 803
Wilson, S., Nutt, D., Alford, C., Argyropoulos, S., Baldwin, D., Bateson, A., Britton, T., Crowe, C., Dijk, D.-J., Espie, C., et al. (2010) · Journal of Psychopharmacology · doi:10.1177/0269881110379307 · Cited by 634
Melatonin as a mitochondria-targeted antioxidant: one of evolution's best ideas
Reiter, R. J., Rosales-Corral, S., Tan, D. X., Jou, M. J., Galano, A., & Xu, B. (2017) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-017-2609-7 · Cited by 558 · cited 1×
“Indeed, there is now strong evidence that melatonin is produced in every animal cell that has mitochondria (13, 14), melatonin being involved, among other functions, in the elimination of free radicals and the regulation of immune response to achieve cytoprotection (15).”
BackgroundMelatonin and inflammation-Story of a double-edged blade
Hardeland, R. (2018) · Journal of Pineal Research · doi:10.1111/jpi.12525 · Cited by 455 · cited 2×
“Collectively, these effects of melatonin are reflected in reduced levels of proinflammatory cytokines and increased production of anti-inflammatory cytokines (31).”
BackgroundA Multicenter, Placebo-controlled Trial of Melatonin for Sleep Disturbance in Alzheimer's Disease
Singer, C., Tractenberg, R. E., Kaye, J., Schafer, K., Gamst, A., Grundman, M., Thomas, R., & Thal, L. J. (2003) · Sleep · doi:10.1093/sleep/26.7.893 · Cited by 407
Cited by
Melatonin’s Impact on Antioxidative and Anti-Inflammatory Reprogramming in Homeostasis and Disease
Chitimus, D. M., Popescu, M. R., Voiculescu, S. E., Panaitescu, A. M., Pavel, B., Zagrean, L., & Zagrean, A.-M. (2020) · Biomolecules · doi:10.3390/biom10091211 · Cited by 354
Cellular Mechanisms of Melatonin: Insight from Neurodegenerative Diseases
Chen, D., Zhang, T., & Lee, T. H. (2020) · Biomolecules · doi:10.3390/biom10081158 · Cited by 140
“Clinical studies have been conducted to explore the effect of exogenous melatonin on clinical symptoms in PD patients [6,190,191].”
BackgroundSafety of higher doses of melatonin in adults: A systematic review and meta-analysis
Menczel Schrire, Z., Phillips, C. L., Chapman, J. L., Duffy, S. L., Wong, G., D’Rozario, A. L., Comas, M., Raisin, I., Saini, B., Gordon, C. J., et al. (2022) · Journal of Pineal Research · doi:10.1111/jpi.12782 · Cited by 133
Mitochondrial Dysfunctions: A Red Thread across Neurodegenerative Diseases
Stanga, S., Caretto, A., Boido, M., & Vercelli, A. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21103719 · Cited by 90
Morris, G., Puri, B. K., Bortolasci, C. C., Carvalho, A., Berk, M., Walder, K., Moreira, E. G., & Maes, M. (2021) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2021.02.037 · Cited by 84
Metadata
- Authors
- Cardinali, D. P.
- Venue
- Frontiers in Endocrinology
- Publisher
- Frontiers Media SA
- Published
- 2019-07-16
- Volume
- 10
- Pages
- 480-480
- ISSN
- 1664-2392 (ISSN-L)
- OpenAlex
- W2960257281
- Cited by
- 197
- References
- 19
- FWCI
- 12.24
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Melatonin: Clinical Perspectives in Neurodegeneration. https://app.cochat.ai/papers/10.3389/fendo.2019.00480
- The paper
- Cardinali, D. P. (2019). Melatonin: Clinical Perspectives in Neurodegeneration. Frontiers in Endocrinology. https://doi.org/10.3389/fendo.2019.00480
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.